CA2108014A1 - 4-aryl-3-(heteroarylureido)quinoline derivatives - Google Patents

4-aryl-3-(heteroarylureido)quinoline derivatives

Info

Publication number
CA2108014A1
CA2108014A1 CA002108014A CA2108014A CA2108014A1 CA 2108014 A1 CA2108014 A1 CA 2108014A1 CA 002108014 A CA002108014 A CA 002108014A CA 2108014 A CA2108014 A CA 2108014A CA 2108014 A1 CA2108014 A1 CA 2108014A1
Authority
CA
Canada
Prior art keywords
ureido
chlorophenyl
bis
quinoline
methylthio
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002108014A
Other languages
English (en)
French (fr)
Inventor
Ernest S. Hamanaka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2108014A1 publication Critical patent/CA2108014A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
CA002108014A 1991-04-26 1992-03-16 4-aryl-3-(heteroarylureido)quinoline derivatives Abandoned CA2108014A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US69232391A 1991-04-26 1991-04-26
US07/692,323 1991-04-26
PCT/US1992/001801 WO1992019614A1 (en) 1991-04-26 1992-03-16 4-aryl-3-(heteroarylureido)quinoline derivatives

Publications (1)

Publication Number Publication Date
CA2108014A1 true CA2108014A1 (en) 1992-10-27

Family

ID=24780107

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002108014A Abandoned CA2108014A1 (en) 1991-04-26 1992-03-16 4-aryl-3-(heteroarylureido)quinoline derivatives

Country Status (20)

Country Link
EP (1) EP0590094A1 (zh)
JP (1) JPH0776215B2 (zh)
CN (1) CN1066068A (zh)
AU (1) AU1879792A (zh)
BR (1) BR9205939A (zh)
CA (1) CA2108014A1 (zh)
CZ (1) CZ395592A3 (zh)
DE (1) DE9290049U1 (zh)
FI (1) FI934710A0 (zh)
HU (1) HUT65748A (zh)
IE (1) IE921330A1 (zh)
IL (1) IL101627A0 (zh)
MX (1) MX9201916A (zh)
NO (1) NO933837L (zh)
NZ (1) NZ242493A (zh)
PT (1) PT100426A (zh)
TW (1) TW197436B (zh)
WO (1) WO1992019614A1 (zh)
YU (1) YU44592A (zh)
ZA (1) ZA922976B (zh)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2125325T3 (es) * 1992-01-23 1999-03-01 Pfizer Derivados de 4-fenil-3-(heteroarilureido)-1,2-dihidro-2-oxoquinolina como agentes antihipercolesterolemicos y antiateroscleroticos.
US5565472A (en) * 1992-12-21 1996-10-15 Pfizer Inc. 4-aryl-3-(heteroarylureido)-1,2-dihydro-2-oxo-quinoline derivatives as antihypercholesterolemic and antiatherosclerotic agents
NZ264063A (en) * 1993-08-13 1995-11-27 Nihon Nohyaku Co Ltd N-(2-phenylpyrid-3-yl)- and n-(4-phenylpyrimidin-5-yl)-n'-phenylurea derivatives and pharmaceutical compositions
US5843957A (en) * 1995-05-19 1998-12-01 Sumitomo Pharmaceuticals Company, Ltd. Naphthyridine derivatives
NZ308228A (en) * 1995-05-31 1999-11-29 Sumitomo Pharma Substituted 1,8-naphthyridine derivatives
NZ335766A (en) * 1996-11-26 2000-11-24 Sumitomo Pharma Naphthyridine derivatives and use as acyl-CoA cholesterol acyl transferase(ACAT) inhibitor as treatment of hyperlipidemia
AU2547399A (en) 1998-02-25 1999-09-15 Sumitomo Pharmaceuticals Company, Limited Pyridone derivatives and process for producing the same
US6452008B2 (en) 1998-02-25 2002-09-17 Sumitomo Pharmaceuticals Company, Limited Pyridone derivatives and process for preparing the same
BRPI0417543A (pt) * 2003-12-12 2007-03-27 Wyeth Corp quinolinas úteis no tratamento de doença cardiovascular
CN103601677B (zh) * 2013-11-19 2015-11-18 清华大学 制备2-烷硫基喹啉衍生物的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE892088L (en) * 1988-07-12 1990-01-12 William Henry Deryk Morris Quinoline derivatives, their production and use
MX22406A (es) * 1989-09-15 1994-01-31 Pfizer Nuevos derivados de n-aril y n-heteroarilamidas y urea como inhibidores de acil coenzima a: acil transferasa del colesterol (acat).
TW205037B (zh) * 1989-10-06 1993-05-01 Takeda Pharm Industry Co Ltd

Also Published As

Publication number Publication date
HUT65748A (en) 1994-07-28
TW197436B (zh) 1993-01-01
HU9303025D0 (en) 1994-01-28
FI934710A (fi) 1993-10-25
JPH0776215B2 (ja) 1995-08-16
PT100426A (pt) 1993-08-31
NO933837L (no) 1993-10-25
AU1879792A (en) 1992-12-21
BR9205939A (pt) 1994-09-27
NZ242493A (en) 1994-08-26
IL101627A0 (en) 1992-12-30
ZA922976B (en) 1993-10-25
CN1066068A (zh) 1992-11-11
FI934710A0 (fi) 1993-10-25
YU44592A (sh) 1994-12-28
MX9201916A (es) 1992-11-01
WO1992019614A1 (en) 1992-11-12
IE921330A1 (en) 1992-11-04
EP0590094A1 (en) 1994-04-06
JPH06501025A (ja) 1994-01-27
DE9290049U1 (de) 1994-01-05
CZ395592A3 (en) 1994-02-16

Similar Documents

Publication Publication Date Title
US5596001A (en) 4-aryl-3-(heteroarylureido)quinoline derivatves
US5885996A (en) Antiproliferative quinazolines
US4818756A (en) 2-pyrimidinyl-1-piperazine derivatives, processes for their preparation and medicaments containing them
US6894057B2 (en) Oxo-azabicyclic compounds
US5063227A (en) Quinazoline-substituted pyridazinone derivatives having cardiotonic activity
AU775194B2 (en) Bis-sulfonamides
CA2221992A1 (en) N,n-di(arylmethyl)cyclic urea derivatives as anti-coagulants
CA2108014A1 (en) 4-aryl-3-(heteroarylureido)quinoline derivatives
US7317014B2 (en) Bio-active pyrimidine molecules
US5565472A (en) 4-aryl-3-(heteroarylureido)-1,2-dihydro-2-oxo-quinoline derivatives as antihypercholesterolemic and antiatherosclerotic agents
Zhu et al. Design, synthesis and anticancer activity of 4-morpholinothieno [3, 2-d] pyrimidine derivatives bearing arylmethylene hydrazine moiety
EP0227450A2 (en) Substituted 5,6-Dialkoxyquinazoline Derivatives
CA2128093C (en) 4-aryl-3-(heteroarylureido)-1,2-dihydro-2-oxoquinoline derivatives as antihypercholesterolemic and antiatherosclerotic agents
US7399760B2 (en) Pyrimidinedione derivatives
EP0144730B1 (en) 2-anilino-1,6-dihydro-6-oxo-5-pyrimidinecarboxylic acid derivatives, processes for the preparation thereof, and antiallergic agent containing the same
JPH0789957A (ja) ビフェニルメチルアミン誘導体
JPWO2004014873A1 (ja) ４−置換キナゾリン−８−カルボン酸アミド誘導体とその薬理上許容される付加塩
US5990118A (en) Purine compounds and xanthine oxidase inhibitors
CA1224785A (en) 5-substituted (1,2,4) triazolo-(1,5-c) pyrimidin-2- amines
Mekheimer et al. Fused quinoline heterocycles VI: Synthesis of 5H‐1‐thia‐3, 5, 6‐triazaaceanthrylenes and 5H‐1‐thia‐3, 4, 5, 6‐tetraazaaceanthrylenes
Tandel et al. Design, synthesis and biological potential of some isoxazole and hydroxypyrimidine derivatives containing pyrido [2, 3-d] pyrimidine nucleus via chalcone series
US5187276A (en) 2-pyrimidinyl-1-piperazine derivatives
NO822445L (no) Fremgangsmaate ved fremstilling av 6-(3,6-dihydro-1(2h)-pyridyl)-pyrimidin-3-oksyder

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued